Practice
Open Access
Novel obesity treatments
Shohinee Sarma, Susan Tran and Michael Fralick
CMAJ November 20, 2023 195 (45) E1546-E1547; DOI: https://doi.org/10.1503/cmaj.230820
Shohinee Sarma
Institute of Health Policy, Management and Evaluation (Sarma, Fralick), University of Toronto, Toronto, Ont.; Division of Endocrinology, Diabetes and Metabolism (Sarma), Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Mass.; Division of Endocrinology (Tran), Department of Medicine, Michael Garron Hospital, University of Toronto; Division of General Internal Medicine (Fralick), Sinai Health System, Toronto, Ont.
MD MPHSusan Tran
Institute of Health Policy, Management and Evaluation (Sarma, Fralick), University of Toronto, Toronto, Ont.; Division of Endocrinology, Diabetes and Metabolism (Sarma), Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Mass.; Division of Endocrinology (Tran), Department of Medicine, Michael Garron Hospital, University of Toronto; Division of General Internal Medicine (Fralick), Sinai Health System, Toronto, Ont.
MD MScMichael Fralick
Institute of Health Policy, Management and Evaluation (Sarma, Fralick), University of Toronto, Toronto, Ont.; Division of Endocrinology, Diabetes and Metabolism (Sarma), Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Mass.; Division of Endocrinology (Tran), Department of Medicine, Michael Garron Hospital, University of Toronto; Division of General Internal Medicine (Fralick), Sinai Health System, Toronto, Ont.
MD PhD
Submit a Response to This Article
Jump to comment:
No Responses have been published for this article.
In this issue
Article extras
Podcast
Article tools
Novel obesity treatments
Shohinee Sarma, Susan Tran, Michael Fralick
CMAJ Nov 2023, 195 (45) E1546-E1547; DOI: 10.1503/cmaj.230820
Jump to section
- Article
- Semaglutide, a glucagon-like peptide-1 receptor agonist (GLP1RA) is a weekly subcutaneous injection for adults with obesity
- As an adjunct to intensive behavioural therapy, semaglutide results in more weight loss and improves measures of cardiometabolic health than behavioural therapy alone
- Tirzepatide, a dual glucose-dependent insulinotropic polypeptide and GLP1RA, is a weekly subcutaneous injection approved for adults with obesity
- Semaglutide and tirzepatide have a similar profile of adverse effects and contraindications
- Potential adverse effects of GLP1RAs continue to be monitored with post-market surveillance
- Footnotes
- References
- Figures & Tables
- Related Content
- Responses
- Metrics
Related Articles
Cited By...
- No citing articles found.